Portal hypertensiv gastropati

K Brinch; S Møller; Jens Henrik Sahl Henriksen; P U Becker

Portal hypertensiv gastropati

K Brinch, S Møller, Jens Henrik Sahl Henriksen, P U Becker

Abstract

Portal hypertensive gastropathy (PHG) as defined by congestive changes in the gastric mucosa owing to increased portal pressure, was first described about ten years ago. Whereas definition and grading of severity are still under debate, there is general agreement that PHG is a new clinical entity. PHG is present in 50-80% of patients with liver cirrhosis. PHG is a major cause of upper gastrointestinal bleeding in patients with portal hypertension (25-90% depending on severity). Presence of portal hypertension is a prerequisite for the development of PHG, and reduction of portal pressure and splanchnic blood flow with beta-adrenergic blockers has shown promising results, but an established medical treatment of PHG does not exist. Trials with new vasoactive drugs are awaited.
Udgivelsesdato: 1995-Nov-13

Bidragets oversatte titel	Portal hypertensive gastropathy
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	157
Udgave nummer	46
Sider (fra-til)	6421-5
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 1995

Citationsformater

@article{fb22a6b02b7e11df8ed1000ea68e967b,

title = "Portal hypertensiv gastropati",

abstract = "Portal hypertensive gastropathy (PHG) as defined by congestive changes in the gastric mucosa owing to increased portal pressure, was first described about ten years ago. Whereas definition and grading of severity are still under debate, there is general agreement that PHG is a new clinical entity. PHG is present in 50-80% of patients with liver cirrhosis. PHG is a major cause of upper gastrointestinal bleeding in patients with portal hypertension (25-90% depending on severity). Presence of portal hypertension is a prerequisite for the development of PHG, and reduction of portal pressure and splanchnic blood flow with beta-adrenergic blockers has shown promising results, but an established medical treatment of PHG does not exist. Trials with new vasoactive drugs are awaited. Udgivelsesdato: 1995-Nov-13",

author = "K Brinch and S M{\o}ller and Henriksen, {Jens Henrik Sahl} and Becker, {P U}",

note = "Keywords: Chronic Disease; Gastric Mucosa; Gastritis; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Hypertension, Portal; Liver Cirrhosis",

year = "1995",

language = "Dansk",

volume = "157",

pages = "6421--5",

journal = "Ugeskrift for l{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "46",

}

TY - JOUR

T1 - Portal hypertensiv gastropati

AU - Brinch, K

AU - Møller, S

AU - Henriksen, Jens Henrik Sahl

AU - Becker, P U

N1 - Keywords: Chronic Disease; Gastric Mucosa; Gastritis; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Hypertension, Portal; Liver Cirrhosis

PY - 1995

Y1 - 1995

N2 - Portal hypertensive gastropathy (PHG) as defined by congestive changes in the gastric mucosa owing to increased portal pressure, was first described about ten years ago. Whereas definition and grading of severity are still under debate, there is general agreement that PHG is a new clinical entity. PHG is present in 50-80% of patients with liver cirrhosis. PHG is a major cause of upper gastrointestinal bleeding in patients with portal hypertension (25-90% depending on severity). Presence of portal hypertension is a prerequisite for the development of PHG, and reduction of portal pressure and splanchnic blood flow with beta-adrenergic blockers has shown promising results, but an established medical treatment of PHG does not exist. Trials with new vasoactive drugs are awaited. Udgivelsesdato: 1995-Nov-13

AB - Portal hypertensive gastropathy (PHG) as defined by congestive changes in the gastric mucosa owing to increased portal pressure, was first described about ten years ago. Whereas definition and grading of severity are still under debate, there is general agreement that PHG is a new clinical entity. PHG is present in 50-80% of patients with liver cirrhosis. PHG is a major cause of upper gastrointestinal bleeding in patients with portal hypertension (25-90% depending on severity). Presence of portal hypertension is a prerequisite for the development of PHG, and reduction of portal pressure and splanchnic blood flow with beta-adrenergic blockers has shown promising results, but an established medical treatment of PHG does not exist. Trials with new vasoactive drugs are awaited. Udgivelsesdato: 1995-Nov-13

M3 - Tidsskriftartikel

C2 - 7483098

SN - 0041-5782

VL - 157

SP - 6421

EP - 6425

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 46

ER -